|
|
| (One intermediate revision not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of GIP with Glutaminase L== | | ==Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of GIP with Glutaminase L== |
| - | <StructureSection load='2l4s' size='340' side='right'caption='[[2l4s]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='2l4s' size='340' side='right'caption='[[2l4s]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[2l4s]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L4S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L4S FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[2l4s]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L4S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L4S FirstGlance]. <br> |
| - | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[2l4t|2l4t]]</div></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">TAX1BP3, TIP1 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | |
| | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l4s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l4s OCA], [https://pdbe.org/2l4s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l4s RCSB], [https://www.ebi.ac.uk/pdbsum/2l4s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l4s ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l4s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l4s OCA], [https://pdbe.org/2l4s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l4s RCSB], [https://www.ebi.ac.uk/pdbsum/2l4s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l4s ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[https://www.uniprot.org/uniprot/TX1B3_HUMAN TX1B3_HUMAN]] May regulate a number of protein-protein interactions by competing for PDZ domain binding sites. Binds CTNNB1 and may thereby act as an inhibitor of the Wnt signaling pathway. Competes with LIN7A for KCNJ4 binding, and thereby promotes KCNJ4 internalization. May play a role in the Rho signaling pathway. May play a role in activation of CDC42 by the viral protein HPV16 E6.<ref>PMID:10940294</ref> <ref>PMID:16855024</ref> <ref>PMID:21139582</ref>
| + | [https://www.uniprot.org/uniprot/TX1B3_HUMAN TX1B3_HUMAN] May regulate a number of protein-protein interactions by competing for PDZ domain binding sites. Binds CTNNB1 and may thereby act as an inhibitor of the Wnt signaling pathway. Competes with LIN7A for KCNJ4 binding, and thereby promotes KCNJ4 internalization. May play a role in the Rho signaling pathway. May play a role in activation of CDC42 by the viral protein HPV16 E6.<ref>PMID:10940294</ref> <ref>PMID:16855024</ref> <ref>PMID:21139582</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 23: |
Line 22: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Banerjee, M]] | + | [[Category: Banerjee M]] |
| - | [[Category: Bhaskaran, R]] | + | [[Category: Bhaskaran R]] |
| - | [[Category: Mohanty, S]] | + | [[Category: Mohanty S]] |
| - | [[Category: Ovee, M]] | + | [[Category: Ovee M]] |
| - | [[Category: Zoetewey, D L]] | + | [[Category: Zoetewey DL]] |
| - | [[Category: Gip]]
| + | |
| - | [[Category: Glutatminase l]]
| + | |
| - | [[Category: Pdz domain]]
| + | |
| - | [[Category: Peptide binding protein]]
| + | |
| Structural highlights
Function
TX1B3_HUMAN May regulate a number of protein-protein interactions by competing for PDZ domain binding sites. Binds CTNNB1 and may thereby act as an inhibitor of the Wnt signaling pathway. Competes with LIN7A for KCNJ4 binding, and thereby promotes KCNJ4 internalization. May play a role in the Rho signaling pathway. May play a role in activation of CDC42 by the viral protein HPV16 E6.[1] [2] [3]
Publication Abstract from PubMed
Glutaminase Interacting Protein (GIP) is composed of a single PDZ domain that interacts with a growing list of partner proteins, including Glutaminase L, that are involved in a number of cell signaling and cancer pathways. Therefore, GIP makes a good target for structure-based drug design. Here we report the solution structures of both free GIP and GIP bound to the C-terminal peptide analog of Glutaminase L. This is the first reported NMR structure of GIP in a complex with one of its binding partners. Our analysis of both free GIP and GIP complexed with the Glutaminase L peptide provides important insights into how a promiscuous binding domain can have affinity for multiple binding partners. Through a detailed chemical shift perturbation analysis and backbone dynamics studies, we demonstrate here that the binding of the Glutaminase L peptide to GIP is an allosteric event. Taken together, the insights reported here lay the groundwork for the future development of a specific inhibitor for GIP.
Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of GIP with Glutaminase L.,Zoetewey DL, Ovee M, Banerjee M, Bhaskaran R, Mohanty S Biochemistry. 2011 Mar 18. PMID:21417405[4]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Reynaud C, Fabre S, Jalinot P. The PDZ protein TIP-1 interacts with the Rho effector rhotekin and is involved in Rho signaling to the serum response element. J Biol Chem. 2000 Oct 27;275(43):33962-8. PMID:10940294 doi:10.1074/jbc.M000465200
- ↑ Alewine C, Olsen O, Wade JB, Welling PA. TIP-1 has PDZ scaffold antagonist activity. Mol Biol Cell. 2006 Oct;17(10):4200-11. Epub 2006 Jul 19. PMID:16855024 doi:10.1091/mbc.E06-02-0129
- ↑ Oliver AW, He X, Borthwick K, Donne AJ, Hampson L, Hampson IN. The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42. Br J Cancer. 2011 Jan 18;104(2):324-31. doi: 10.1038/sj.bjc.6606026. Epub 2010, Dec 7. PMID:21139582 doi:10.1038/sj.bjc.6606026
- ↑ Zoetewey DL, Ovee M, Banerjee M, Bhaskaran R, Mohanty S. Promiscuous Binding at the Crossroads of Numerous Cancer Pathways: Insight from the Binding of GIP with Glutaminase L. Biochemistry. 2011 Mar 18. PMID:21417405 doi:10.1021/bi102055y
|
